Recombinant Mouse Low-density lipoprotein receptor class A domain-containing protein 3 (Ldlrad3)

What is the molecular structure of mouse Ldlrad3 and how does it compare to human LDLRAD3?

Mouse Ldlrad3 is a conserved plasma membrane protein belonging to the LDL scavenger receptor family. The protein contains multiple domains including three low-density lipoprotein receptor type-A (LA) modules in its extracellular portion. The full-length human isoform of LDLRAD3 shares 96% sequence identity with mouse Ldlrad3, differing by only three amino acids in the ectodomain . This high conservation suggests evolutionary importance across species.

The protein exists in multiple isoforms, including a full-length version and a shorter isoform with a 32-amino acid deletion near the N-terminal region (Δ32). Research indicates that the full-length isoform, but not the truncated version, supports VEEV infection when expressed in cells lacking endogenous Ldlrad3 .

Which domains of Ldlrad3 are critical for VEEV binding and infection?

Domain 1 (D1) of Ldlrad3 has been identified as both necessary and sufficient for VEEV binding and infection. Experimental evidence using truncation mutants (D1 only, D1+D2, or D2+D3) demonstrated that constructs containing D1 (either alone or with D2) supported VEEV infection, while D2+D3 did not . This indicates the critical role of D1 in virus recognition.

Structural studies further reveal that D1 of LDLRAD3 is a low-density lipoprotein receptor type-A module that binds to VEEV by wedging into a cleft created by two adjacent E2–E1 heterodimers in one trimeric spike, engaging domains A and B of E2 and the fusion loop in E1 . This binding mechanism is remarkably similar to how arthritogenic alphaviruses interact with the structurally unrelated MXRA8 receptor, albeit with a much smaller interface in the LDLRAD3-VEEV interaction .

What is the tissue distribution of Ldlrad3 expression in mice?

Ldlrad3 shows a broad expression pattern across multiple tissues in mice. Based on TaqMan qRT-PCR analysis spanning the deletion region in exons 2 and 3, Ldlrad3 mRNA has been detected in numerous tissues in wild-type mice . Particularly notable is its expression in:

• Neurons of the brain (confirmed by in situ hybridization)

• Epithelial cells of the gastrointestinal tract

• Myeloid cells

• Muscle tissues

This wide distribution pattern may explain the diverse tropism observed with VEEV infection. The neuronal expression is especially significant given VEEV's encephalitic nature and neurotropism .

What are the optimal methods for generating recombinant mouse Ldlrad3 for research?

The generation of recombinant mouse Ldlrad3 typically involves the following methodology:

• Construct Design: Design constructs containing the entire ectodomain or specific domains (particularly D1) of Ldlrad3. For therapeutic applications, fusion proteins such as Ldlrad3-D1-Fc have shown promise .

• Expression Systems: Mammalian expression systems (typically HEK293 cells) are preferred for proper folding and post-translational modifications of Ldlrad3.

• Purification Strategy:

  • Initial capture using affinity chromatography (often with His-tags or Fc-fusion tags)

  • Further purification by size exclusion chromatography to ensure monomeric preparations

  • Quality control by SDS-PAGE and binding assays to confirm functionality

• Validation: Confirm proper folding and functionality through binding assays with VEEV particles, typically using surface plasmon resonance or enzyme-linked immunosorbent assays.

For monomeric LDLRAD3 ectodomain constructs specifically, researchers have successfully employed previously described methods that yield functionally active protein capable of binding to VEEV .

How can researchers validate Ldlrad3 knockout models?

Validation of Ldlrad3 knockout models requires multiple complementary approaches:

• Genomic Verification:

  • PCR-based genotyping spanning the deletion region

  • Sequencing of the targeted locus to confirm the intended genetic modification

• Transcript Analysis:

  • Quantitative RT-PCR using primers spanning the deletion site

  • TaqMan primer sets have been successfully employed spanning the deletion region in exons 2 and 3 of Ldlrad3

  • No signal should be detected in knockout mice using these methods

• Protein Expression Analysis:

  • Western blotting of tissues known to express Ldlrad3

  • Flow cytometry to measure surface expression on relevant cell types

  • Immunohistochemistry or immunofluorescence staining

• Functional Validation:

  • Challenge with VEEV to confirm resistance to infection

  • Viral replication assays in tissues and cells derived from knockout mice

  • Complementation studies by reintroducing Ldlrad3 to restore VEEV susceptibility

Studies with Ldlrad3Δ14/Δ14 mice have utilized these approaches to confirm successful gene deletion and assess the functional consequences on VEEV infection .

What techniques are most effective for studying Ldlrad3-virus interactions?

Several complementary techniques have proven effective for investigating Ldlrad3-virus interactions:

• Cryo-Electron Microscopy (Cryo-EM):

  • Near-atomic-resolution reconstructions of VEEV virus-like particles alone and in complex with LDLRAD3 ectodomains have provided detailed structural insights

  • This technique revealed that D1 of LDLRAD3 binds to VEEV by wedging into a cleft created by E2-E1 heterodimers

• Binding and Internalization Assays:

  • Flow cytometry-based binding assays using labeled virus particles

  • Confocal microscopy to track virus internalization in cells expressing different Ldlrad3 variants

  • These approaches demonstrated that Ldlrad3 enhances both virus attachment and internalization

• Domain Mapping Studies:

  • Expression of truncation mutants (D1 only, D1+D2, D2+D3)

  • Surface expression confirmation using N-terminal tags

  • Infection assays with reporter viruses to assess functionality

  • These methods established that D1 is necessary and sufficient for VEEV binding

• Competition Assays:

  • Anti-VEEV antibody binding competition assays validated structural models of the Ldlrad3-VEEV interface

  • Soluble Ldlrad3-D1-Fc constructs competed with cellular Ldlrad3 for VEEV binding

How does Ldlrad3 contribute to VEEV neurotropism and pathogenesis?

Ldlrad3 plays a critical role in VEEV neurotropism and pathogenesis through multiple mechanisms:

• Facilitating Neuronal Infection:

  • Ldlrad3 is expressed on neurons in the brain, making them permissive to VEEV infection

  • In situ hybridization studies have confirmed neuronal expression of Ldlrad3 mRNA in wild-type mice

  • Ldlrad3-deficient mice show reduced infection of neurons in different brain regions upon VEEV challenge

• Multiple Stages of Pathogenesis:

  • Ldlrad3 is required for efficient VEEV infection both prior to and after central nervous system invasion

  • Ldlrad3-deficient mice survive both intranasal and intracranial VEEV inoculation, indicating its importance even after the virus reaches the brain

• Viral Entry and Spread:

  • By functioning as an attachment and entry receptor, Ldlrad3 enhances VEEV binding to and internalization into neurons

  • This leads to productive infection, viral replication, and subsequent spread throughout the CNS

• Impact on Disease Progression:

  • Studies comparing viral RNA levels in various tissues between wild-type and Ldlrad3-deficient mice show significantly reduced viral loads in the latter

  • At 12 hours post-infection, viral RNA was detected in the olfactory bulb and cerebral cortex of wild-type mice but not Ldlrad3-deficient mice

  • This suggests Ldlrad3 facilitates early neuroinvasion by VEEV

The critical role of Ldlrad3 in neurotropism is further evidenced by the fact that Ldlrad3-deficient mice survive VEEV challenge, demonstrating that Ldlrad3-dependent entry is a primary determinant of VEEV pathogenesis .

Does Ldlrad3 serve as a receptor for other alphaviruses besides VEEV?

Ldlrad3 shows remarkable specificity for VEEV among alphaviruses. Experimental evidence demonstrates:

• Specificity Testing: When Ldlrad3 was edited in cell culture models, substantial reduction in infection was observed with VEEV TrD strain, but no difference was observed with Eastern equine encephalitis virus (EEEV) .

• Extended Testing: This phenotype was confirmed with SINV-EEEV chimeras and extended to SINV-WEEV (MacMillan) chimeras, indicating Ldlrad3 specificity for VEEV .

• Other Alphaviruses: No loss of infection was observed for arthritogenic alphaviruses (SINV and MAYV) when Ldlrad3 was edited .

• Non-Alphavirus Testing: Similarly, unrelated viruses including a rhabdovirus (Vesicular stomatitis virus) and a flavivirus (West Nile virus) showed no dependence on Ldlrad3 for infection .

This specificity is noteworthy, particularly considering that other members of the low-density lipoprotein receptor family, including LDLR itself, VLDLR, and ApoER2, have been identified as entry factors for different alphaviruses . The structural basis for this specificity likely involves the unique interaction between domain 1 of Ldlrad3 and the specific conformation of VEEV envelope proteins.

What is the comparative role of Ldlrad3 in peripheral versus CNS infection by VEEV?

Ldlrad3 plays important but somewhat distinct roles in peripheral and CNS infection by VEEV:

Peripheral Infection:

CNS Infection:

• Ldlrad3 appears critical for neuroinvasion, as viral RNA was detected in the olfactory bulb and cerebral cortex of wild-type mice but not Ldlrad3-deficient mice at 12 hours post-infection .

• Remarkably, Ldlrad3-deficient mice survive both intranasal and intracranial VEEV inoculation, indicating that Ldlrad3 is essential for productive infection of neurons even when the virus is directly introduced into the CNS .

• This suggests Ldlrad3 functions as a primary neuronal receptor for VEEV, and its absence significantly limits viral replication in the brain regardless of how the virus reaches the CNS.

The dual importance of Ldlrad3 in both peripheral dissemination and CNS infection highlights its potential as a therapeutic target for preventing VEEV disease at multiple stages of pathogenesis.

How effective are Ldlrad3-based decoy receptors in inhibiting VEEV infection?

Ldlrad3-based decoy receptors have shown remarkable efficacy in inhibiting VEEV infection in both in vitro and in vivo models:

• In Vitro Efficacy:

  • Anti-Ldlrad3 antibodies and a Ldlrad3-D1-Fc fusion protein effectively blocked VEEV infection in cell culture

  • The D1 domain alone was sufficient for this inhibitory effect, consistent with its role as the key virus-binding domain

• In Vivo Protection:

  • Administration of Ldlrad3-D1-Fc abolished disease caused by multiple VEEV subtypes, including highly virulent strains

  • This suggests broad efficacy against diverse VEEV variants

• Mechanism of Action:

  • The decoy receptor likely functions by competing with cellular Ldlrad3 for binding to VEEV particles

  • By preventing virus attachment to cellular receptors, the initial step of the viral life cycle is blocked

• Advantages:

  • High specificity for VEEV, minimizing off-target effects

  • Targets an essential step in viral infection

  • May be effective against multiple VEEV strains due to conservation of the receptor-binding site

The development of such decoy receptor fusion proteins represents a promising strategy for preventing severe VEEV infection and disease in humans, particularly given the lack of approved vaccines or therapeutics for VEEV .

What factors should be considered when designing Ldlrad3-targeted therapeutics?

Several critical factors should be considered when designing Ldlrad3-targeted therapeutics:

• Domain Selection:

  • Domain 1 (D1) of Ldlrad3 is necessary and sufficient for VEEV binding, making it the optimal domain for therapeutic development

  • Including additional domains may affect stability or manufacturing but offers limited functional benefit

• Protein Engineering Considerations:

  • Fusion partners (e.g., Fc region) can enhance stability and half-life

  • Potential immunogenicity must be assessed

  • Optimization of linker sequences between D1 and fusion partners may impact activity

• Formulation and Delivery:

  • Blood-brain barrier penetration is crucial for targeting CNS infection

  • Route of administration affects efficacy (intravenous vs. intranasal delivery)

  • Stability under storage conditions must be optimized

• Timing of Administration:

  • Prophylactic use may differ from post-exposure treatment efficacy

  • Window of opportunity for effective intervention needs definition

  • Potential for combination with other antivirals or immune modulators

• Viral Escape:

  • Potential for viral mutations that escape Ldlrad3 binding should be monitored

  • Combination approaches may mitigate resistance development

• Cross-Reactivity:

  • Specificity for VEEV versus other alphaviruses must be maintained

  • Potential interference with endogenous Ldlrad3 function should be evaluated

By carefully considering these factors, researchers can develop optimized Ldlrad3-targeted therapeutics with the greatest potential for clinical translation against VEEV infection.

What structural features determine the specificity of Ldlrad3 for VEEV?

The specificity of Ldlrad3 for VEEV is determined by several key structural features of the receptor-virus interaction:

• Binding Interface:

  • Domain 1 of LDLRAD3 binds VEEV by wedging into a cleft created by two adjacent E2–E1 heterodimers in one trimeric spike

  • This interaction engages domains A and B of E2 and the fusion loop in E1

  • The relatively small interface compared to other alphavirus-receptor interactions may contribute to specificity

• Comparative Structural Analysis:

  • Despite functional differences, VEEV engages LDLRAD3 in a manner structurally similar to how arthritogenic alphaviruses bind to the unrelated MXRA8 receptor

  • This convergent evolution of binding mechanisms suggests a constrained set of effective virus-receptor interactions

• E2 Protein Determinants:

  • Specific residues in domains A and B of the E2 protein of VEEV likely contribute to Ldlrad3 recognition

  • These residues may differ in Eastern and Western equine encephalitis viruses, explaining their inability to use Ldlrad3

• Domain 1 Architecture:

  • The specific fold and surface properties of Ldlrad3 D1 create a complementary interface for VEEV binding

  • The LA module structure, with its characteristic disulfide bond pattern, creates a specialized binding surface

Understanding these structural determinants is crucial for developing targeted therapeutics and predicting potential viral escape mutations. Future research using directed evolution or systematic mutagenesis could further elucidate the molecular basis of this specificity.

How does Ldlrad3 interact with the cellular machinery during VEEV entry?

The interaction between Ldlrad3 and cellular machinery during VEEV entry represents an important but incompletely understood aspect of viral pathogenesis:

• Internalization Pathway:

  • While Ldlrad3 clearly enhances virus attachment and internalization, the specific endocytic pathway utilized (clathrin-dependent, caveolin-dependent, or macropinocytosis) remains to be fully characterized

  • Understanding which cellular factors cooperate with Ldlrad3 during internalization could identify additional therapeutic targets

• Conformational Changes:

  • How binding to Ldlrad3 might trigger conformational changes in the viral envelope proteins to facilitate membrane fusion is not fully elucidated

  • The timing and compartment of membrane fusion events following Ldlrad3-mediated entry requires further investigation

• Co-receptors and Accessory Factors:

  • The potential role of co-receptors or accessory cellular factors in VEEV entry, especially in the context of Ldlrad3 binding, remains a critical question

  • The observation that Ldlrad3 deficiency does not completely abrogate infection suggests redundant entry mechanisms

• Signaling Consequences:

  • Whether Ldlrad3 engagement by VEEV triggers specific cellular signaling cascades that facilitate infection is unknown

  • Such signaling could potentially modulate immune responses or cellular metabolism to favor viral replication

Advanced research techniques including proximity labeling, live-cell imaging, and proteomic approaches will be essential to fully map the interactions between Ldlrad3 and cellular machinery during VEEV entry.

What are the most promising approaches for developing next-generation Ldlrad3-targeted antivirals?

Several innovative approaches show promise for developing next-generation Ldlrad3-targeted antivirals:

• Multimerized Decoy Receptors:

  • Engineering multimerized forms of Ldlrad3 D1 could enhance avidity for VEEV

  • Higher avidity might translate to greater potency and extended half-life

• Structure-Guided Optimization:

  • Using the known crystal structure of the Ldlrad3-VEEV complex to design optimized binding interfaces

  • Computational design approaches could enhance binding affinity without sacrificing specificity

• Bi-specific Inhibitors:

  • Creating molecules that simultaneously target Ldlrad3-binding sites and other critical epitopes on VEEV

  • This approach might raise the barrier to viral escape and enhance potency

• Targeted Delivery Systems:

  • Developing nanoparticle or exosome-based delivery systems that can effectively transport Ldlrad3 decoys across the blood-brain barrier

  • This would enhance therapeutic efficacy against established CNS infection

• Gene Therapy Approaches:

  • Temporary downregulation of neuronal Ldlrad3 expression through RNA interference or CRISPR-based approaches

  • This strategy could render neurons temporarily resistant to VEEV infection during outbreaks

• Combination Therapies:

  • Rational combinations of Ldlrad3-targeted therapeutics with antivirals targeting other stages of the viral life cycle

  • This multi-targeted approach could enhance efficacy and reduce the potential for resistance

• Cross-Protective Designs:

  • Engineering chimeric receptor decoys that combine binding domains for multiple alphavirus receptors

  • Such molecules could potentially provide protection against multiple encephalitic alphaviruses

The development of these next-generation approaches will require interdisciplinary collaboration between structural biologists, virologists, immunologists, and drug delivery experts to overcome the challenges of targeting CNS infections effectively.